Therapeutic HPV DNA vaccines

Ken Yu Lin, Elena Roosinovich, Barbara Ma, Chien Fu Hung, T. C. Wu

Research output: Contribution to journalReview article

76 Citations (Scopus)

Abstract

It is now well established that most cervical cancers are causally associated with HPV infection. This realization has led to efforts to control HPV-associated malignancy through prevention or treatment of HPV infection. Currently, commercially available HPV vaccines are not designed to control established HPV infection and associated premalignant and malignant lesions. To treat and eradicate pre-existing HPV infections and associated lesions which remain prevalent in the U.S. and worldwide, effective therapeutic HPV vaccines are needed. DNA vaccination has emerged as a particularly promising form of therapeutic HPV vaccines due to its safety, stability and ability to induce antigen-specific immunity. This review focuses on improving the potency of therapeutic HPV vaccines through modification of dendritic cells (DCs) by [1] increasing the number of antigen-expressing/antigen-loaded DCs, [2] improving HPV antigen expression, processing and presentation in DCs, and [3] enhancing DC and T cell interaction. Continued improvement in therapeutic HPV DNA vaccines may ultimately lead to an effective DNA vaccine for the treatment of HPV-associated malignancies.

Original languageEnglish (US)
Pages (from-to)86-112
Number of pages27
JournalImmunologic Research
Volume47
Issue number1-3
DOIs
StatePublished - Jul 1 2010
Externally publishedYes

Fingerprint

Papillomavirus Vaccines
DNA Vaccines
Dendritic Cells
Antigen Presentation
Infection
Antigens
Therapeutics
Cell Communication
Uterine Cervical Neoplasms
Immunity
Neoplasms
Vaccination
T-Lymphocytes
Safety
DNA

Keywords

  • Cervical cancer
  • DNA vaccines
  • HPV
  • HPV E6
  • HPV E7
  • Therapeutic vaccine

ASJC Scopus subject areas

  • Immunology

Cite this

Lin, K. Y., Roosinovich, E., Ma, B., Hung, C. F., & Wu, T. C. (2010). Therapeutic HPV DNA vaccines. Immunologic Research, 47(1-3), 86-112. https://doi.org/10.1007/s12026-009-8141-6

Therapeutic HPV DNA vaccines. / Lin, Ken Yu; Roosinovich, Elena; Ma, Barbara; Hung, Chien Fu; Wu, T. C.

In: Immunologic Research, Vol. 47, No. 1-3, 01.07.2010, p. 86-112.

Research output: Contribution to journalReview article

Lin, KY, Roosinovich, E, Ma, B, Hung, CF & Wu, TC 2010, 'Therapeutic HPV DNA vaccines', Immunologic Research, vol. 47, no. 1-3, pp. 86-112. https://doi.org/10.1007/s12026-009-8141-6
Lin KY, Roosinovich E, Ma B, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Immunologic Research. 2010 Jul 1;47(1-3):86-112. https://doi.org/10.1007/s12026-009-8141-6
Lin, Ken Yu ; Roosinovich, Elena ; Ma, Barbara ; Hung, Chien Fu ; Wu, T. C. / Therapeutic HPV DNA vaccines. In: Immunologic Research. 2010 ; Vol. 47, No. 1-3. pp. 86-112.
@article{f7950f1c3a354db99165516f005f1e41,
title = "Therapeutic HPV DNA vaccines",
abstract = "It is now well established that most cervical cancers are causally associated with HPV infection. This realization has led to efforts to control HPV-associated malignancy through prevention or treatment of HPV infection. Currently, commercially available HPV vaccines are not designed to control established HPV infection and associated premalignant and malignant lesions. To treat and eradicate pre-existing HPV infections and associated lesions which remain prevalent in the U.S. and worldwide, effective therapeutic HPV vaccines are needed. DNA vaccination has emerged as a particularly promising form of therapeutic HPV vaccines due to its safety, stability and ability to induce antigen-specific immunity. This review focuses on improving the potency of therapeutic HPV vaccines through modification of dendritic cells (DCs) by [1] increasing the number of antigen-expressing/antigen-loaded DCs, [2] improving HPV antigen expression, processing and presentation in DCs, and [3] enhancing DC and T cell interaction. Continued improvement in therapeutic HPV DNA vaccines may ultimately lead to an effective DNA vaccine for the treatment of HPV-associated malignancies.",
keywords = "Cervical cancer, DNA vaccines, HPV, HPV E6, HPV E7, Therapeutic vaccine",
author = "Lin, {Ken Yu} and Elena Roosinovich and Barbara Ma and Hung, {Chien Fu} and Wu, {T. C.}",
year = "2010",
month = "7",
day = "1",
doi = "10.1007/s12026-009-8141-6",
language = "English (US)",
volume = "47",
pages = "86--112",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "1-3",

}

TY - JOUR

T1 - Therapeutic HPV DNA vaccines

AU - Lin, Ken Yu

AU - Roosinovich, Elena

AU - Ma, Barbara

AU - Hung, Chien Fu

AU - Wu, T. C.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - It is now well established that most cervical cancers are causally associated with HPV infection. This realization has led to efforts to control HPV-associated malignancy through prevention or treatment of HPV infection. Currently, commercially available HPV vaccines are not designed to control established HPV infection and associated premalignant and malignant lesions. To treat and eradicate pre-existing HPV infections and associated lesions which remain prevalent in the U.S. and worldwide, effective therapeutic HPV vaccines are needed. DNA vaccination has emerged as a particularly promising form of therapeutic HPV vaccines due to its safety, stability and ability to induce antigen-specific immunity. This review focuses on improving the potency of therapeutic HPV vaccines through modification of dendritic cells (DCs) by [1] increasing the number of antigen-expressing/antigen-loaded DCs, [2] improving HPV antigen expression, processing and presentation in DCs, and [3] enhancing DC and T cell interaction. Continued improvement in therapeutic HPV DNA vaccines may ultimately lead to an effective DNA vaccine for the treatment of HPV-associated malignancies.

AB - It is now well established that most cervical cancers are causally associated with HPV infection. This realization has led to efforts to control HPV-associated malignancy through prevention or treatment of HPV infection. Currently, commercially available HPV vaccines are not designed to control established HPV infection and associated premalignant and malignant lesions. To treat and eradicate pre-existing HPV infections and associated lesions which remain prevalent in the U.S. and worldwide, effective therapeutic HPV vaccines are needed. DNA vaccination has emerged as a particularly promising form of therapeutic HPV vaccines due to its safety, stability and ability to induce antigen-specific immunity. This review focuses on improving the potency of therapeutic HPV vaccines through modification of dendritic cells (DCs) by [1] increasing the number of antigen-expressing/antigen-loaded DCs, [2] improving HPV antigen expression, processing and presentation in DCs, and [3] enhancing DC and T cell interaction. Continued improvement in therapeutic HPV DNA vaccines may ultimately lead to an effective DNA vaccine for the treatment of HPV-associated malignancies.

KW - Cervical cancer

KW - DNA vaccines

KW - HPV

KW - HPV E6

KW - HPV E7

KW - Therapeutic vaccine

UR - http://www.scopus.com/inward/record.url?scp=77953958731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953958731&partnerID=8YFLogxK

U2 - 10.1007/s12026-009-8141-6

DO - 10.1007/s12026-009-8141-6

M3 - Review article

VL - 47

SP - 86

EP - 112

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 1-3

ER -